← All indications
Pemphigoid, Bullous
A chronic and relatively benign subepidermal blistering disease usually of the elderly and without histopathologic acantholysis.
Drugs by status
Phase 4 trials (6)
Phase 3 trials (9)
Phase 2 trials (13)
Phase 1 trials (1)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (6)
Organization Involved with Phase 2 Indications (20)
- Roche
- Eli Lilly
- Biogen
- Akari Therapeutics
- Novartis
- Immune Pharmaceuticals
- TWi Biotechnology, Inc.
- Harvard University
- Duke University
- University of Bern
- Mayo Clinic
- Tel Aviv University
- University of California, San Francisco
- University of Munster
- University of Reims
- Istituto Dermopatico dell'Immacolata, Roma
- University of Nice Sophia Antipolis
- University of Alabama, Birmingham
- Dompe Pharmaceuticals
- Alkahest, Inc.
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (2)